Literature DB >> 23002204

Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/- mice.

Richard L Price1, Katherine Bingmer, Lualhati Harkins, O Hans Iwenofu, Chang-Hyuk Kwon, Charles Cook, Christopher Pelloski, E Antonio Chiocca.   

Abstract

Cytomegalovirus (CMV) has been detected in several human cancers, but it has not proven to be oncogenic. However, recent studies have suggested mechanisms through which cytomegalovirus may modulate the tumor environment, encouraging its study as a positive modifier of tumorigenesis. In this study, we investigated the effects of cytomegalovirus infection in Trp53 heterozygous mice. Animals were infected with murine cytomegalovirus (MCMV) after birth at 2 days (P2) or 4 weeks of age and then monitored for tumor formation. Mice injected at 2 days of age developed tumors at a high frequency (43%) by 9 months of age. In contrast, only 3% of mock-infected or mice infected at 4 weeks developed tumors. The majority of tumors from P2 MCMV-infected mice were pleomorphic rhabdomyosarcomas (RMS) harboring MCMV DNA, RNA, and protein. An examination of clinical cases revealed that human RMS (embryonal, alveolar, and pleomorphic) harbored human cytomegalovirus IE1 and pp65 protein as well as viral RNA. Taken together, our findings offer support for the hypothesis that cytomegalovirus contributes to the development of pleomorphic RMS in the context of Trp53 mutation, a situation that occurs with high frequency in human RMS. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23002204      PMCID: PMC3500419          DOI: 10.1158/0008-5472.CAN-12-2425

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  A spatially and temporally restricted mouse model of soft tissue sarcoma.

Authors:  David G Kirsch; Daniela M Dinulescu; John B Miller; Jan Grimm; Philip M Santiago; Nathan P Young; G Petur Nielsen; Bradley J Quade; Christopher J Chaber; Christian P Schultz; Osamu Takeuchi; Roderick T Bronson; Denise Crowley; Stanley J Korsmeyer; Sam S Yoon; Francis J Hornicek; Ralph Weissleder; Tyler Jacks
Journal:  Nat Med       Date:  2007-08-05       Impact factor: 53.440

Review 2.  Rhabdomyosarcoma.

Authors:  Arnold C Paulino; Mehmet Fatih Okcu
Journal:  Curr Probl Cancer       Date:  2008 Jan-Feb       Impact factor: 3.187

3.  Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.

Authors:  Ninib Baryawno; Afsar Rahbar; Nina Wolmer-Solberg; Chato Taher; Jenny Odeberg; Anna Darabi; Zahidul Khan; Baldur Sveinbjörnsson; O-M FuskevÅg; Lova Segerström; Magnus Nordenskjöld; Peter Siesjö; Per Kogner; John Inge Johnsen; Cecilia Söderberg-Nauclér
Journal:  J Clin Invest       Date:  2011-09-26       Impact factor: 14.808

4.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

Authors:  Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

5.  Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma.

Authors:  C A Felix; C C Kappel; T Mitsudomi; M M Nau; M Tsokos; G D Crouch; P D Nisen; N J Winick; L J Helman
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

6.  Mechanisms of p53 loss in human sarcomas.

Authors:  L M Mulligan; G J Matlashewski; H J Scrable; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time.

Authors:  Jürgen Weitz; Christina R Antonescu; Murray F Brennan
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

8.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

Review 9.  Epidemiology of cytomegaloviral infections: recommendations for prevention and control.

Authors:  I M Onorato; D M Morens; W J Martone; S K Stansfield
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

10.  Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma.

Authors:  Simona Ognjanovic; Ghyslaine Martel; Carlos Manivel; Magali Olivier; Erica Langer; Pierre Hainaut
Journal:  Sarcoma       Date:  2012-03-07
View more
  20 in total

Review 1.  Cytomegalovirus and glioblastoma; controversies and opportunities.

Authors:  Sean E Lawler
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

Review 2.  Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.

Authors:  Michael Quinn; Dan A Erkes; Christopher M Snyder
Journal:  Immunotherapy       Date:  2016-01-20       Impact factor: 4.196

3.  Immunohistochemical Characterization of Sarcomas in Trp53+/- Haploinsufficient Mice.

Authors:  M P Jokinen; D L Morgan; H C Price; R A Herbert; T Saddler; D Dixon
Journal:  Toxicol Pathol       Date:  2017-08       Impact factor: 1.902

Review 4.  Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options.

Authors:  Cecilia Söderberg-Nauclér; John Inge Johnsen
Journal:  World J Exp Med       Date:  2015-02-20

5.  STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.

Authors:  Nicole A Wilski; Colby Stotesbury; Christina Del Casale; Brian Montoya; Eric Wong; Luis J Sigal; Christopher M Snyder
Journal:  J Immunol       Date:  2020-04-13       Impact factor: 5.422

6.  Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Authors:  Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

7.  Human cytomegalovirus-encoded US28 may act as a tumor promoter in colorectal cancer.

Authors:  Zhen-Zhai Cai; Jian-Gang Xu; Yu-Hui Zhou; Ji-Hang Zheng; Ke-Zhi Lin; Shu-Zhi Zheng; Meng-Si Ye; Yun He; Chang-Bao Liu; Zhan-Xiong Xue
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

8.  Expression of Oncogenic Alleles Induces Multiple Blocks to Human Cytomegalovirus Infection.

Authors:  Shihao Xu; Xenia Schafer; Joshua Munger
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

9.  Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.

Authors:  Inti Peredo; Anders Helldén; Nina Wolmer-Solberg; Anton Pohanka; Giuseppe Stragliotto; Afsar Rahbar; Lars Ståhle; Bo-Michael Bellander; Cecilia Söderberg-Nauclér
Journal:  BMJ Case Rep       Date:  2015-12-15

10.  Dual analysis of the murine cytomegalovirus and host cell transcriptomes reveal new aspects of the virus-host cell interface.

Authors:  Vanda Juranic Lisnic; Marina Babic Cac; Berislav Lisnic; Tihana Trsan; Adam Mefferd; Chitrangada Das Mukhopadhyay; Charles H Cook; Stipan Jonjic; Joanne Trgovcich
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.